US6707031075 - Common Stock
NUVALENT INC-A
NASDAQ:NUVL (5/1/2024, 3:30:01 PM)
After market: 70.65 0 (0%)70.65
+1.77 (+2.57%)
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 89 full-time employees. The company went IPO on 2021-07-29. Its lead product candidate, NVL-520 is a novel ROS1-selective inhibitor designed to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases. Its second lead product candidate, NVL-655, is a brain-penetrant ALK-selective inhibitor designed to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that may limit the use of first, second, and third generation ALK inhibitors. The Company’s product candidate also includes NVL-330, is a brain-penetrant HER2-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20, treating brain metastases, and avoiding treatment-limiting adverse events, including due to off-target inhibition of wild-type EGFR.
NUVALENT INC-A
One Broadway, 14Th Floor
Cambridge MASSACHUSETTS
P: 18573577000
CEO: James R. Porter
Employees: 89
Website: https://www.nuvalent.com/
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Nuvalent's lung cancer drug NVL-520 receives breakthrough therapy designation from the FDA for ROS1-positive metastatic NSCLC treatment.
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Here you can normally see the latest stock twits on NUVL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: